title: One hundred consecutive living kidney donors: modern issues and outcomes.
abstract: In order to define current issues and outcomes of living kidney donation, 100 consecutive living donors operated on between July 1996 and March 2001 were evaluated. The 64 women and 36 men ranged in age from 19 to 72 yr (mean 42.5 yr), and 65 were related to the recipient while 35 were unrelated donors. Hospital admission the morning of surgery and use of a minimal open approach to the donor kidney were standard, as were post-operative epidural pain control and plans for short hospital stay. The 100 donors were hospitalized for 2 (25), 3 (48), 4 (18), 5 (8), or 6 (1) days, with an average length of stay of 3.12 d (range 2-6 d). The mean charge for kidney donor hospitalization was 14,470 dollars (range 9671-22,808 dollars). There were no major intra or immediate post-operative complications. Six rehospitalizations occurred for post-donation nausea, vomiting, dehydration (n = 2); spinal headache; pneumonia and wound haematoma; and late wound reexploration (one hernia and one nerve entrapment). All donors returned to pre-operative functional status within 6 d to 6 wk of donation. All kidneys functioned immediately in the 100 recipients (50 women, 50 men) who averaged 46.6 yr of age (range 17-69 yr); recipient length of stay averaged 3.81 d (range 2-15 d). All donors survived in excellent health; recipient graft and patient survival, respectively, are 87 and 90% through the entire 5-yr period. Excellent long-term outcomes for living kidney donors may be accomplished using minimal open surgical technique, post-operative epidural pain control and plans for a brief hospitalization. Expansion of living donor resources in renal transplant programs may grow as unrelated kidney donation and non-directed donation as well as minimally invasive (open and laparoscopic) techniques evolve.
authors.affiliation: The Jacksonville Transplant Center at Shands Jacksonville Medical Center, Jacksonville, FL 32209, USA.
authors.forename: Thomas G
authors.initials: TG
authors.lastname: Peters
authors.forename: Suzanne M
authors.initials: SM
authors.lastname: Repper
authors.forename: Mia C
authors.initials: MC
authors.lastname: Vincent
authors.forename: Colleen A
authors.initials: CA
authors.lastname: Schonberg
authors.forename: Kenneth W
authors.initials: KW
authors.lastname: Jones
authors.forename: Ivan
authors.initials: I
authors.lastname: Cruz
authors.forename: Ronald K
authors.initials: RK
authors.lastname: Charlton
authors.forename: Christopher S
authors.initials: CS
authors.lastname: McCullough
authors.forename: Richard D
authors.initials: RD
authors.lastname: Hunter
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects / Q000191:economics; D007902:Length of Stay; D019520:Living Donors / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged
chemical_list: D007166:Immunosuppressive Agents